Eisai has partnered with Geisinger to assess whether a machine-learning model can accurately identify people with cognitive impairment — which may suggest early signs of dementia. Machine learning is a form of artificial intelligence (AI) that uses algorithms to analyze data, learn from its analyses, and then make…
NNI-362, Neuronascent’s investigational treatment for Alzheimer’s disease, was safe and reduced blood levels of an Alzheimer’s biomarker in a Phase 1a trial of the therapy in healthy, older adults. The primary goal of the trial (NCT04074837), which enrolled 56 adults between the ages of 50 and 72, was…
The Centers for Medicare and Medicaid Services (CMS), in a final national policy decision, is allowing Medicare to cover the cost of Aduhelm (aducanumab) and other medicines in its class given accelerated approval only for Alzheimer’s disease patients enrolled in qualifying clinical trials. Should Adulhelm or future amyloid-targeting monoclonal antibodies be…
Alzamend Neuro’s experimental oral therapy for dementia related to Alzheimer’s disease may deliver the benefits of marketed lithium-based treatments but with fewer side effects, data from a completed Phase 1 trial show. A 150 milligrams (mg) dose of the therapy, called AL001, led to similar levels of lithium…
Treatment with the investigational candidate SAGE-718 was generally well-tolerated and associated with cognitive improvements in people with Alzheimer’s disease, according to preliminary results from the LUMINARY Phase 2 clinical trial. The therapy’s developer, Sage Therapeutics, presented these findings in a talk, titled “SAGE-718 in…
Biogen, the co-developer of Aduhelm (aducanumab) has submitted the final protocol for ENVISION — the Phase 4 post-marketing study of the therapy in early Alzheimer’s disease — to the U.S. Food and Drug Administration (FDA) for review and approval, the company has announced. Screening of the first…
Prothena has begun testing single ascending doses (SAD) of PRX012, its investigational anti-amyloid beta antibody therapy, in a Phase 1 clinical trial with healthy volunteers and people with Alzheimer’s disease. This follows the recent approval of the company’s investigational new drug (IND) application for PRX012 by the U.S.
Most adults in the U.S., as well as many doctors, have difficulty distinguishing between the early stages of Alzheimer’s disease and cognitive changes due to normal aging, according to the latest annual report from the Alzheimer’s Association. The report draws on responses to surveys, one of adult Americans…
A dual vaccine targeting both amyloid plaques and tangled fibers made up of tau — two abnormal protein aggregates that build up in the brain of those with Alzheimer’s — may have potential to treat and prevent the disease. Prothena, its developer, has found preclinical evidence that the…
Atuzaginstat (COR388), Cortexyme’s investigational oral therapy, effectively suppressed the activity of its target — toxic enzymes called gingipains — and was associated with reductions in several disease biomarkers in people with mild-to-moderate Alzheimer’s, according to updated data from the Phase 2/3 GAIN clinical trial. Similar to previously reported…
Get regular updates to your inbox.